Clarus Therapeutics is a pharmaceutical company preparing for the commercial launch of REXTORO, a first-in-class oral T formulation to treat men diagnosed with T deficiency together with an associated medical condition known as hypogonadism. REXTORO is a softgel capsule that contains a testosterone (T) prodrug, T undecanoate, or TU, formulated to foster absorption via the intestinal lymphatic pathway.



We believe JATENZO® will expand treatment options for adult males diagnosed with conditions associated with a deficiency or absence of endogenous testosterone:

  • Primary hypogonadism (congenital or acquired)
  • Hypogonadotropic hypogonadism (congenital or acquired)

Jatenzo inTune Trial

JATENZO was approved based on the efficacy results from the Phase 3 inTUne trial.  In this trial, 145 (87%) of the 166 hypogonadal men who received JATENZO had a mean total testosterone concentration (Cavg) within the normal eugonadal range at the end of treatment. 

Testosterone Deficiency

The Endocrine Society defines hypogonadism in men as a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone (androgen deficiency) and a normal number of spermatozoa due to disruption of one or more levels of the hypothalamic-pituitary-testicular axis.